The marketing of FatigFix is a collaboration between Chrysalis and the technology holder Phynova Group, a UK company developing prescription as well as OTC drugs for healthcare and personal care markets.
Double-blind, placebo-controlled studies involving middle age individuals with fatigue symptoms showed that FatigFix reduced symptoms of fatigue such as lethargy, clarity of thought, frequency of headaches.
FatigFix also increased the energy levels and improved the quality of sleep after only few weeks of taking the product.
FatigFix, which is being offered as a functional health food ingredient, can be formulated into various dosage forms such as stick-pack, tablets/capsules and drinks, Chrysalis said.
Chrysalis director Mark Broughton said FatigFix works as an ‘adaptogenic formula’ and its clinical studies demonstrate not only a reduction in day time fatigue, but also a significant improvement in sleep patterns and quality of sleep.
Phynova is planning to commercialise FatigFix in the USA, Far East, Middle East and Africa, Latin America, and some European countries.